Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 28Breast Diseases 3Advanced Breast Cancer 2Vitamin D Deficiency 1Triple Negative Breast Neoplasms 1Recurrence 1Obesity 1Nutrition Disorders 1Neoplasms 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma 1Camurati-Engelmann Syndrome 1Bulbo-Spinal Atrophy, X-Linked 1Breast Carcinoma In Situ 1Breast Cancer Organoids 1Arthritis 1Arthralgia 1

Interventions

Tamoxifen 3Neoadjuvant Therapy 2Amplified Fragment Length Polymorphism Analysis 2Ultrasonography 1Saline Solution 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Mammography 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Immunoenzyme Techniques 1Fulvestrant 1DNA Methylation 1Chemotherapy, Adjuvant 1Carboplatin 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Intraductal, Noninfiltrating × Anastrozole × Clear all
NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

National Cancer Institute (NCI)

Phase 2 Unknown
2,000 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡